Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Histopathology

• Publication date

  2013-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/his.12188PMID 23889174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision.

  2012cited by this paper
• Localization of decorin gene expression in normal human breast tissue and in benign and malignant tumors of the human breast

  2012cited by this paper
• Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression.

  2012influential reference
• Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

  2012cited by this paper
• Stromal biomarkers in breast cancer development and progression

  2012cited by this paper
• Clinical and functional significance of loss of caveolin‐1 expression in breast cancer‐associated fibroblasts

  2012cited by this paper
• Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.

  2012cited by this paper
• Increased diagnosis and detection rates of carcinoma in situ of the breast

  2012cited by this paper
• Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24

  2012cited by this paper
• Breast cancer and the stromal factor. The "prometastatic healing process" hypothesis.

  2011cited by this paper
• Prognostic markers and long‐term outcomes in ductal carcinoma in situ of the breast treated with excision alone

  2011influential reference
• Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

  2011cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

  2010cited by this paper
• Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ.

  2010cited by this paper
• Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

  2010cited by this paper
• A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• The expression of syndecan-1, syndecan-4 and decorin in healthy human breast tissue during the menstrual cycle

  2010cited by this paper
• Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations

  2010cited by this paper
• Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence

  2010cited by this paper
• Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation

  2010cited by this paper
• Prognostic Significance of Oncogenic Markers in Ductal Carcinoma In Situ of the Breast: A Clinicopathologic Study

  2009cited by this paper
• A taxonomy of epithelial human cancer and their metastases

  2009cited by this paper
• Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer

  2009influential reference
• Stromal cell expression of caveolin-1 predicts outcome in breast cancer.

  2009cited by this paper
• The extracellular matrix regulates cancer progression and therapy response: implications for prognosis and treatment.

  2009cited by this paper
• The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions

  2008influential reference
• An antimetastatic role for decorin in breast cancer.

  2008cited by this paper
• Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis

  2008cited by this paper
• Stromal myofibroblasts are drivers of invasive cancer growth

  2008cited by this paper
• p27KIP‐1 cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP‐1 correlates with hormone receptor status but not with local recurrence

  2007cited by this paper
• Pathologic variables predictive of breast events in patients with ductal carcinoma in situ.

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Clinicopathological Significance of Stromal Myofibroblasts in Invasive Ductal Carcinoma of the Breast

  2004cited by this paper
• The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast

  2004cited by this paper
• The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast.

  2003cited by this paper
• Breast Cancer Stromal Myxoid Changes Are Associated with Tumor Invasion and Metastasis: A Central Role for Hyaluronan

  2003cited by this paper
• Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer.

  2003cited by this paper
• Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.

  2003influential reference
• World Health Organization Classification of Tumours

  2002cited by this paper
• CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions

  2002cited by this paper
• An Anti-oncogenic Role for Decorin

  2000cited by this paper
• Lumican and decorin are differentially expressed in human breast carcinoma

  2000cited by this paper
• Targeted Disruption of Decorin Leads to Abnormal Collagen Fibril Morphology and Skin Fragility

  1997cited by this paper
• Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.

  1993cited by this paper
• Noninvasive Breast Carcinoma: Results of a National Survey by the American College of Surgeons

  1980cited by this paper
• Microinvasive carcinoma.

  1979cited by this paper

• A detailed protocol for open and low-cost six-plex immunofluorescence (Flex-6 mIHF) with a proof-of-concept study on breast cancer tissue.

  2026cites this paper
• Tumour‐infiltrating lymphocytes, tertiary lymphoid structures and myxoid stroma predict upstaging of ductal carcinoma in situ in breast biopsies

  2025cites this paper
• From ductal carcinoma in situ to invasive breast cancer: the prognostic value of the extracellular microenvironment

  2024cites this paper
• Human Ductal Carcinoma In Situ: Advances and Future Perspectives.

  2023cites this paper
• Breast cancer microenvironment and obesity: challenges for therapy

  2022cites this paper
• Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast

  2021cites this paper
• Plasma Levels of Decorin Increased in Patients during the Progression of Breast Cancer

  2021cites this paper
• High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial

  2021cites this paper
• Obesity reduces mammary epithelial cell TGFβ1 activity through macrophage‐mediated extracellular matrix remodeling

  2020cites this paper
• Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent

  2020cites this paper
• The prognostic significance of immune microenvironment in breast ductal carcinoma in situ

  2020cites this paper
• Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study

  2019cites this paper
• Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses

  2019cites this paper
• The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ

  2019cites this paper
• Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast.

  2019cites this paper
• Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS

  2019cites this paper
• Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results in substantial interobserver concordance

  2018cites this paper
• Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast

  2018cites this paper
• Collagen Alignment and Recurrence of DCIS—Letter

  2018cites this paper
• Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study

  2018cites this paper
• Prognostic Significance of Tumour Infiltrating Lymphocytes in Ductal Carcinoma in Situ of the Breast

  2018cites this paper
• Stromal inflammation, necrosis and HER2 overexpression in ductal carcinoma in situ of the breast: another causality dilemma?

  2017cites this paper
• Proteomic characterization of microdissected breast tissue environment provides a protein‐level overview of malignant transformation

  2017cites this paper
• Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression

  2017cites this paper
• Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis

  2017cites this paper
• Ductal carcinoma in situ – update on risk assessment and management

  2016cites this paper
• The Baader–Meinhof phenomenon in ductal carcinoma in situ of the breast

  2016cites this paper
• Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen.

  2016cites this paper
• Reduced decorin expression in the tumor stroma correlates with tumor proliferation and predicts poor prognosis in patients with I–IIIA non-small cell lung cancer

  2016cites this paper
• Chromatin-Remodeling Complex SWI/SNF Controls Multidrug Resistance by Transcriptionally Regulating the Drug Efflux Pump ABCB1.

  2016cites this paper
• Reply to the Baader–Meinhof phenomenon in ductal carcinoma in situ of the breast

  2016cites this paper
• Biomarkers in ductal carcinoma in situ

  2016cites this paper
• Identifying progression predictors of breast ductal carcinoma in situ

  2016cites this paper
• Fibroblast-induced matrix remodeling paves the path for invasion

  2015cites this paper
• Tumor-environment biomimetics delay peritoneal metastasis formation by deceiving and redirecting disseminated cancer cells.

  2015cites this paper
• Prognostic value of stromal decorin expression in patients with breast cancer: a meta-analysis.

  2015influential citation
• Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype

  2014influential citation
• Differential regulation of extracellular matrix protein expression in carcinoma-associated fibroblasts by TGF-β1 regulates cancer cell spreading but not adhesion

  2014cites this paper
• Potential

  1984cites this paper